| Remdesivir in patients with acute or chronic kidney disease and COVID-19 ML Adamsick, RG Gandhi, MR Bidell, RH Elshaboury, RP Bhattacharyya, ... Journal of the American Society of Nephrology 31 (7), 1384-1386, 2020 | 199 | 2020 |
| Baseline procalcitonin as a predictor of bacterial infection and clinical outcomes in COVID-19: A case-control study NJ Atallah, HM Warren, MB Roberts, RH Elshaboury, MR Bidell, ... PLoS One 17 (1), e0262342, 2022 | 34 | 2022 |
| Clinical outcomes and economic impact of oritavancin for gram-positive infections: a single academic medical center health system experience LE Brownell, ML Adamsick, EK McCreary, JP Vanderloo, EJ Ernst, ... Drugs-Real World Outcomes 7, 13-19, 2020 | 19 | 2020 |
| Therapeutic drug concentrations of isavuconazole following the administration of isavuconazonium sulfate capsules via gastro‐jejunum tube: a case report ML Adamsick, RH Elshaboury, T Gift, MK Mansour, CN Kotton, RG Gandhi Transplant Infectious Disease 21 (2), e13048, 2019 | 10 | 2019 |
| Remdesivir use and outcomes during the FDA COVID-19 emergency use authorization period RH Elshaboury, MM Monk, LM Bebell, MR Bidell, ML Adamsick, ... Therapeutic Advances in Infectious Disease 8, 20499361211046669, 2021 | 6 | 2021 |
| Remdesivir in COVID-19 Patients with Impaired Renal Function Reply ML Adamsick, RP Bhattacharyya, ME Sise JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 32 (2), 519-520, 2021 | 1 | 2021 |
| Risk of serotonin syndrome with isoniazid ME O’Brien, RG Gandhi, CN Kotton, ML Adamsick Antimicrobial Agents and Chemotherapy 65 (1), 10.1128/aac. 01455-20, 2020 | 1 | 2020 |
| 756. Impact of Infectious Diseases Pharmacists as Part of an Interdisciplinary OPAT Team Managing Vancomycin ML Adamsick, RG Gandhi, SN Steiger, MR Bidell, SB Nelson, KL Ard, ... Open Forum Infectious Diseases 6 (Suppl 2), S337, 2019 | 1 | 2019 |
| Pharmacist discharge summary: Impact of inpatient to community pharmacist handoff at hospital discharge L Kerstenetzky-Brenny, ML Adamsick, RL Lauscher, KA Kennelty, ... Journal of the American Pharmacists Association 63 (1), 198-203. e4, 2023 | | 2023 |
| 1155. Short vs. Long Symptom Duration Prior to Remdesivir for Hospitalized Patients with COVID-19 RH Elshaboury, ML Adamsick, J Huang, M Winkler, M Ghebremichael, ... Open Forum Infectious Diseases 9 (Supplement_2), ofac492. 993, 2022 | | 2022 |
| Short vs. Long Symptom Duration Prior to Remdesivir for Hospitalized Patients with COVID-19 RH Elshaboury, ML Adamsick, J Huang, M Winkler, M Ghebremichael, ... Open Forum Infectious Diseases, S495-S496, 2022 | | 2022 |
| Therapeutic drug monitoring of flucytosine in a cardiac transplant patient receiving continuous veno‐venous hemofiltration and intermittent hemodialysis: A case report KN Williams, MR Bidell, ML Adamsick, RH Elshaboury, MB Roberts, ... Transplant Infectious Disease 23 (4), e13575, 2021 | | 2021 |
| Retrospective Analysis of Vancomycin Use in Post-Lung Transplant Patients for Chest Tube Prophylaxis E Yanqui, J Clark, M Adamsick, G Waldman 2021 ACCP Virtual Poster Symposium (May 25 and 26), 2021 | | 2021 |
| 1482. Local validation of the drug resistance in pneumonia clinical prediction score at a large academic medical center and a community hospital JL Reinhard, RH Elshaboury, BD Hayes, J Mallada, ML Paras, MR Bidell, ... Open Forum Infectious Diseases 7 (Suppl 1), S742, 2020 | | 2020 |
| 61. Evaluation of the Impact of a Micafungin Time-Out Protocol for Hospitalized Patients KN Williams, RH Elshaboury, AR Letourneau, ML Adamsick, RG Gandhi, ... Open Forum Infectious Diseases 7 (Suppl 1), S51, 2020 | | 2020 |
Ramy ElshabouryMassachusetts General HospitalVerified email at mgh.harvard.edu
